[{"orgOrder":0,"company":"InfoRLife SA","sponsor":"Navamedic","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Other Small Molecule","year":"2022","type":"Agreement","leadProduct":"Clindamycin Hydrochloride","moa":"||50S ribosomal protein L1","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"InfoRLife SA","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"InfoRLife SA \/ Navamedic","highestDevelopmentStatusID":"15","companyTruncated":"InfoRLife SA \/ Navamedic"},{"orgOrder":0,"company":"University of Melbourne","sponsor":"Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Antibiotic","year":"2021","type":"Inapplicable","leadProduct":"Cefazolin","moa":"||Bacterial penicillin-binding protein","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"University of Melbourne","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"University of Melbourne \/ Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit","highestDevelopmentStatusID":"11","companyTruncated":"University of Melbourne \/ Berry Consultants | McGill University Health Centre Research Institute | Menzies School of Health Research | Aotearoa Clinical Trials | Queensland University of Technology | Sunnybrook Health Sciences Centre | Tan Tock Seng Hospital | Telethon Kids Instit"},{"orgOrder":0,"company":"Spaarne Gasthuis","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Gastroenterology","country":"","productType":"Other Small Molecule","year":"2025","type":"Inapplicable","leadProduct":"Gentamicin Sulfate","moa":"||Bacterial 70S ribosome","graph1":"Gastroenterology","graph2":"Phase III","graph3":"Spaarne Gasthuis","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Spaarne Gasthuis \/ ZonMw","highestDevelopmentStatusID":"10","companyTruncated":"Spaarne Gasthuis \/ ZonMw"},{"orgOrder":0,"company":"Johnson & Johnson Innovative Medicine","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Antibody","year":"2023","type":"Inapplicable","leadProduct":"Amivantamab","moa":"||Hepatocyte growth factor receptor | Epidermal growth factor receptor erbB1","graph1":"Oncology","graph2":"Approved FDF","graph3":"Johnson & Johnson Innovative Medicine","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Johnson & Johnson Innovative Medicine \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Johnson & Johnson Innovative Medicine \/ Inapplicable"},{"orgOrder":0,"company":"Leiden University Medical Center","sponsor":"Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Undisclosed","year":"2024","type":"Inapplicable","leadProduct":"C. Difficile Spore","moa":"||Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Undisclosed","graph3":"Leiden University Medical Center","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Leiden University Medical Center \/ Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne","highestDevelopmentStatusID":"1","companyTruncated":"Leiden University Medical Center \/ Helmholtz Centre for Infection Research | GSK | University of Oxford | University of Cologne"}]

Find Clinical Drug Pipeline Developments & Deals for Dalacin

Dalacin
Drugs in Dev.
Full Screen View

Weekly News Recap
#Phispers

Stock Recap
#PipelineProspector

cayman pipeline prospector

Contact Supplier

Access all COS suppliers
Check all USDMF suppliers

Contact Us
PharmaScopic.com

Dalacin

ACCESS ALL DATA, CHEMISTRY

ACTIVE PHARMA INGREDIENTS

39 API Suppliers, 17 USDMF, 10 CEP/COS, 1 JDMF, 3 EU WC, 2 KDMF, 12 NDC API, 14 Listed Suppliers, $ API Reference Price

DEVELOPMENTS

1 Drugs in Development

1 Drugs in Development

INTERMEDIATES

1 Intermediate Suppliers

1 Intermediate Suppliers

FINISHED DOSAGE FORMULATIONS

217 FDF Dossiers, 34 FDA Orange Book, 67 Europe, 26 Canada, 12 Australia, 15 South Africa, 63 Listed Dossiers

DRUG PRODUCT COMPOSITIONS

CAPSULE;ORAL - EQ 150MG BASE, CAPSULE;ORAL - EQ 300MG BASE, CAPSULE;ORAL - EQ 75MG BASE

RELATED EXCIPIENT COMPANIES

3 SPI Pharma, 8 DKSH, 2 Gangwal Healthcare, 3 Nanjing Well Pharmaceutical, 4 ACG Worldwide, 2 Actylis, 1 Aeon Procare, 3 Anhui Sunhere Pharmaceutical Excipients Co.,Ltd, 8 BASF, 3 DFE Pharma, 2 Finar, 3 Gangwal Chemicals, 2 Ingredion Pharma Solutions, 16 Kerry, 3 Lonza Capsugel, 8 Microlex e.U, 1 Nitika Pharmaceutical Specialities, 4 Pluviaendo, 1 Prachin Chemical, 1 Qualicaps, 12 Roquette, 2 Seppic, 2 Shanghai Shenmei Pharmaceutical Technology Co., Ltd, 3 Sigachi Industries, 1 Silverline Chemicals, 1 Valens Pharmachem, 1 Vasa Pharmachem

EXCIPIENTS BY APPLICATIONS

31 Fillers, Diluents & Binders, 19 Direct Compression, 16 Granulation, 14 Lubricants & Glidants, 10 Coating Systems & Additives, 8 Thickeners and Stabilizers, 8 Empty Capsules, 6 Topical, 6 Parenteral, 6 Taste Masking, 5 Chewable & Orodispersible Aids, 5 Co-Processed Excipients, 5 Film Formers & Plasticizers, 4 Emulsifying Agents, 3 Coloring Agents, 3 Controlled & Modified Release, 3 Disintegrants & Superdisintegrants, 3 Solubilizers, 1 Surfactant & Foaming Agents, 1 API Stability Enhancers

DIGITAL CONTENT

24 News #PharmaBuzz

24 News #PharmaBuzz

GLOBAL SALES INFORMATION

28 US Medicaid Prescriptions, 61 Regulatory FDF Prices

MARKET PLACE

34 APIs, 12 FDF Dossiers

REF. STANDARDS & IMPURITIES

2 EDQM, 3 Others

ANALYTICAL

1 Analytical Methods

1 Analytical Methods

Xls

Filters

×

filter

Company Name

filter

Year

filter

DEALS // DEV.

filter

Country

filter

Sponsor

filter

Therapeutic Area

filter

Study Phase

filter

Deal Type

filter

Product Type

filter

Dosage Form

filter

Lead Product

filter

Target

All Developments

Therapeutic Area by Lead Product

Study Phase by Lead Product

Company by Lead Product

Top Deals by Deal Size (USD bn)

Reset All

01

Lee Pharma

India

CPhI WW Frankfurt

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Lead Product(s) : Adapalene,Clindamycin Hydrochloride

Therapeutic Area : Dermatology

Study Phase : Phase III

Sponsor : Zhaoke Ophthalmology

Deal Size : Inapplicable

Deal Type : Inapplicable

A Study to Evaluate the Efficacy and Safety of Adapalene-Clindamycin Combination Gel in the Treatment of Acne ...

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

August 06, 2018

Lead Product(s) : Adapalene,Clindamycin Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase III

Sponsor : Zhaoke Ophthalmology

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

02

Lee Pharma

India

CPhI WW Frankfurt

Lee Pharma Ltd: Global supplier of certified APIs and formulations, driven by innovation and regulatory excellence.

Lead Product(s) : Adapalene,Clindamycin Hydrochloride

Therapeutic Area : Dermatology

Study Phase : Phase I/ Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Compound Adapalene and Clindamycin Hydrochloride Gel in Treatment of Patients With Acne

Details : Undisclosed

Product Name : Undisclosed

Product Type : Other Small Molecule

Upfront Cash : Inapplicable

November 01, 2015

Lead Product(s) : Adapalene,Clindamycin Hydrochloride

Therapeutic Area : Dermatology

Highest Development Status : Phase I/ Phase II

Sponsor : Inapplicable

Deal Size : Inapplicable

Deal Type : Inapplicable

Stock Recap
#PipelineProspector

Data Compilation
#PharmaFlow

03

Spaarne Gasthuis

Country

EPSC

Not Confirmed

04

Leiden University Medical Center

Country

EPSC

Not Confirmed

05

Johnson & Johnson Innovative Medicine

U.S.A

EPSC

Not Confirmed

06

InfoRLife SA

Country

EPSC

Not Confirmed

07

University of Melbourne

Country

EPSC

Not Confirmed

08

Prisma Health-Upstate

Country

EPSC

Not Confirmed

09

Akorn Pharmaceuticals

U.S.A

EPSC

Not Confirmed

10

Derm Research

Country

EPSC

Not Confirmed